Heart Rate Variability (HRV)

Heart rate variability (HRV) measures the beat-to-beat variation in time between heartbeats, reflecting autonomic nervous system balance between sympathetic and parasympathetic activity. The claim: higher HRV indicates better autonomic flexibility and predicts lower mortality risk, while reduced HRV is a marker of autonomic dysfunction associated with cardiovascular and all-cause death.

A comprehensive 2022 systematic review and meta-analysis pooling 32 studies and two individual-participant datasets, spanning 37 samples and 38,008 participants across healthy and patient populations, found lower HRV parameter values significantly predicted higher mortality consistently across ages, sexes, continents, and recording durations [1]. In a specific sub-analysis comparing the lowest quartile of 5-minute root mean square of successive differences (RMSSD, a common time-domain HRV metric) against the other quartiles, the combined hazard ratio was 1.56 (95% CI 1.32-1.85) for mortality [1]. In cardiovascular disease patients specifically, a separate meta-analysis of 28 cohort studies (n=3,094) found lower HRV was associated with a pooled hazard ratio of 2.27 (95% CI 1.72-3.00) for all-cause death and 1.41 (95% CI 1.16-1.72) for cardiovascular events, with the all-cause mortality association significant in acute myocardial infarction patients but not consistently in heart failure patients specifically [2]. A more recent 2025 meta-analysis focused on heart failure alone (10 studies, n=10,544) found impaired HRV, particularly the SDNN time-domain measure, carried a pooled effect size of 1.99 (95% CI 1.36-2.61) for mortality, and improved risk stratification beyond ejection fraction and NYHA functional class, especially for predicting sudden cardiac death (hazard ratio range 2.1-3.2) [3].

How to measure it: clinically, HRV is derived from a continuous ECG recording, commonly 5 minutes or 24 hours, calculating time-domain metrics such as SDNN and RMSSD or frequency-domain metrics [4]. Consumer wearables estimate HRV using photoplethysmography or single-lead ECG, typically reporting RMSSD overnight, which correlates reasonably with clinical-grade measurement but with more noise and device-to-device variability. Bryan Johnson's Blueprint protocol reports HRV as a routinely tracked panel item, an n=1 self-report rather than trial data [5][6].

How to intervene on it: aerobic exercise training, slow-paced breathing practices, adequate sleep, and reducing alcohol intake are all supported by randomized or controlled trial evidence to improve HRV over weeks to months; overtraining, poor sleep, illness, and chronic stress reliably lower it. HRV is also one of the more responsive biomarkers to short-term lifestyle changes, making it a popular day-to-day readiness metric in consumer wearables, distinct from its longer-horizon mortality-prediction role in clinical cohorts.

Critics note substantial heterogeneity across studies (I² often exceeding 90% in pooled analyses), reflecting major differences in recording duration, HRV metric used, and population studied, which complicates drawing one universal HRV number as a target. HRV is also highly context-dependent day to day (affected by illness, alcohol, sleep, and stress), so single readings, especially from consumer wearables using imperfect algorithms, are much less informative than trends over time from clinical-grade measurement.

The plain takeaway: reduced HRV is a consistently replicated predictor of mortality across cardiovascular disease and general populations, with effect sizes comparable to major traditional risk factors in some analyses, but the heterogeneity across studies means no single HRV number applies universally, and daily wearable readings are best used to track personal trends over time rather than compared against population averages.